Drugs and psychosis project: A multi-centre European study on comorbidity

Drug and Alcohol Review

Volumn 28, Issue 4, 2009, Pages 379-389

  Baldacchino, Alex ^a,b   Blair, Hannah ^a,b   Scherbaum, Norbert ^c   Grosse Vehne, Eva ^c   Riglietta, Marco ^d   Tidone, Laura ^d   Criaco, Caterina ^d   Marelli, Maria C ^d   Sommer, Borge ^e   Tan, Liz ^e   Little, Hilary ^f   Ghodse, Hamid ^f  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c Universitaetskilinikum/Rheinsche Essen   (Germany)

^d OSPEDALI RIUNITI   (Italy)

^e Ringkobing Country Psychiatric Unit   (Denmark)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Comorbidity; Drug substance abuse; Psychosis

Indexed keywords

ADDICTION; ADULT; AGE; ARTICLE; CLINICAL TRIAL; CULTURAL FACTOR; EUROPE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHIATRIC DEPARTMENT; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; PSYCHOSIS; STATISTICS; SUBSTANCE ABUSE;

ADULT; AGE FACTORS; CROSS-CULTURAL COMPARISON; DIAGNOSIS, DUAL (PSYCHIATRY); EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 70349305236     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2009.00063.x     Document Type: Article

References (41)

1. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis induced psychosis and subsequent schizophrenia spectrum disorders: follow up study of 535 incident cases. Br J Psychiatry 2005;187:510-15.
2. Caspari D. Cannabis and schizophrenia: results of a follow up study. Eur Arch Psychiatry Clin Neurosci 1999;249: 45-9.
3. Chaudry H, Moss H, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict 1991;86: 1075-81.
4. Fergusson D, Horwood L, Ridder E. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005;100:354-66.
5. Grenn B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005;187:306-13.
6. McGuire P, Jones P, Harvey I, et al. Cannabis and acute psychosis. Schizophr Res 1994;13:161-8.
7. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared cognition at 10 year follow up. Schizophr Res 2005;75:135-7.
8. Corkery J, Baldacchino A. Definition and classification in co-morbidity. In: Baldacchino A, Corkery J, eds. European Collaborating Centres in Addiction Studies (ECCAS) Monograph Series 4: Comorbidity: perspectives across Europe. London: ECCAS; 2006:3-42.
9. Kaiser R, Löhrer F, Morgan V, Hambrecht M. Changes in the pattern of substance abuse after the onset of psychosis. Aust N Z J Psychiatr 2005;39:467-72.
10. Sevy S, Robinson D, Solloway S, et al. Correlates of substance misuse in patients with first episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104:374.
11. Timko C, Chen S, Sempel J, Barnett P. Dual Diagnosis patients in community or hospital care: one-year outcomes and health care utilisation and costs. J Ment Health 2006; 15:163-77.
12. McCrone P, Menezes P, Johnson S, et al. Service use and costs of people with dual diagnosis in South London. Acta Psychiatr Scand 2000;101:464-72.
13. Hodges C-L, Paterson S, Taikato M, McGarrol S, Crome I, Baldacchino A. Co-morbid mental health and substance misuse in Scotland: substance misuse research. Edinburgh: Scottish Executive, 2006.
14. Basu D, Malhotra A, Bhagat A, Varma V. Cannabis psychosis and acute schizophrenia: a case control study from India. Addict Ment Health 1999;5:71-3.
15. Lambert M, Conus P, Lubman D, et al. The impact of substance use disorders on clinical outcome in 643 patients with first episode psychosis. Acta Psychiatr Scand 2005;112: 141-8.
16. Berk M, Brook S, Nur F. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomised control trial. Int J Psychiatry Clin Pract 2000;4:139-42.
17. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003;28:48-54.
18. Grace R, Shenfield G, Tennant C. Cannabis and psychosis in acute psychiatric admissions. Drug and Alcohol Rev 2000;19:287-90.
19. Verdoux H, Tournier M, Cougnard A. Impact of substance use on the onset and course of early psychosis. Schizophr Res 2005;79:69-75.
20. Broome M, Woolley J, Tabraham P, et al. What causes the onset of psychosis? Schizophr Res 2005;79:23-34.
21. Sørensen H, Jepson P, Haastrup S, Juel K. Drug use pattern, co-morbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005;111: 249.
22. Grech A, Van Os J, Jones P, Lewis S, Murray R. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005;20:349-53.
23. Wade D, Harrigan S, Edwards J, Burgess P, Whelan G, McGorry P. Patterns and predictors of substance use disorders and daily tobacco use in first episode psychosis. Aust N Z J Psychiatry 2005;39:898.
24. Korkeila J, Svirskis T, Heinimaa M, et al. Substance abuse and related diagnosis in early psychosis. Compr Psychiatry 2005;46:447-52.
25. Abou-Saleh M, Janca A. The epidemiology of substance misuse and co-morbid psychiatric disorders. Acta Neuro Psychiatr 2004;16:3-8.
26. Folstein M, Folstein S, McHugh P. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-98.
27. Bebbington P. Welcome to ICD-10 and welcome to SCAN. Soc Psychiatry Psychiatr Epidemiol 1992;27: 255-7.
28. Pomerleau C, Carlton S, Lutzke M, Flessland K, Pomerleau O. Reliability of the Fragerstrom tolerance questionnaire and the Fragerstrom test for nicotine dependence. Addict Behav 1994;19:33-9.
29. Pull C, Wittchen H. CIDI, SCAN and IPDE: structured diagnostic interviews for ICD-10 and DSM-III-R. Eur Psychiat 1991;6:277-85.
30. Wittchen H. Reliability and validity studies of the WHOComposite International Diagnostic Interview (DIDI): a critical review. J Psychiatry Res 1994;28:57-84.
31. Kay S, Fizbein A, Opler L. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS). Schizophr Bull 1987;13:261-79.
32. Kay S, Opler L, Lindenmeyer J. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British J Psychiatry 1989;155(Suppl. 7):59-65.
33. Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999;14:366-71.
34. Mathers D, Ghodse A. Cannabis and psychotic illness. Br J Psychiatry 1992;161:648-53.
35. Thornicroft G, Meadows G, Politi P. Is 'cannabis psychosis' a distinct category? Eur Psychiatry 1992;7:277-82.
36. Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148:224-30.
37. Margolese H, Malchy L, Negrete J, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004;67:166.
38. Gandhi D, Bogrov M, Osher F, Myers C. A comparison of the patterns of drug use among patients with or without severe mental illness. Am J Addiction 2003;12:424-31.
39. Stefanis N, Delespaul P, Henquet C, Bakoula C, Stefanis C, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99: 1333-41.
40. Lowe A, Abou-Saleh M. The British experience of dualdiagnosis in the National Health Service. Acta Neuropsychiatr 2004;16:41-6.
41. Nilson M, Fridell M, Griffiths P. Definition and classification in comorbidity. In: Baldacchino A, Corkery J, eds. European Collaborating Centres on Addiction Studies (ECCAS) Monograph Series 4: Comorbidity: perspectives across Europe. London: ECCAS, 2006:349-61.